Sarepta Therapeutics Inc (SRPT)
114.23
+3.73
(+3.38%)
USD |
NASDAQ |
Nov 22, 16:00
114.23
0.00 (0.00%)
After-Hours: 20:00
Sarepta Therapeutics Cash from Operations (Quarterly): -70.70M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -70.70M |
| June 30, 2024 | 14.94M |
| March 31, 2024 | -242.08M |
| December 31, 2023 | -54.66M |
| September 30, 2023 | -114.71M |
| June 30, 2023 | -122.23M |
| March 31, 2023 | -209.40M |
| December 31, 2022 | -92.39M |
| September 30, 2022 | -64.96M |
| June 30, 2022 | -66.82M |
| March 31, 2022 | -101.18M |
| December 31, 2021 | -29.33M |
| September 30, 2021 | -124.33M |
| June 30, 2021 | -109.15M |
| March 31, 2021 | -180.37M |
| December 31, 2020 | -174.54M |
| September 30, 2020 | -238.19M |
| June 30, 2020 | -107.60M |
| March 31, 2020 | 627.79M |
| December 31, 2019 | -163.80M |
| September 30, 2019 | -67.43M |
| June 30, 2019 | -79.00M |
| March 31, 2019 | -146.23M |
| December 31, 2018 | -122.42M |
| September 30, 2018 | -113.32M |
| Date | Value |
|---|---|
| June 30, 2018 | -117.25M |
| March 31, 2018 | -35.67M |
| December 31, 2017 | -31.06M |
| September 30, 2017 | -57.90M |
| June 30, 2017 | -85.15M |
| March 31, 2017 | -57.89M |
| December 31, 2016 | -81.23M |
| September 30, 2016 | -60.62M |
| June 30, 2016 | -43.28M |
| March 31, 2016 | -60.69M |
| December 31, 2015 | -31.27M |
| September 30, 2015 | -46.31M |
| June 30, 2015 | -28.53M |
| March 31, 2015 | -43.35M |
| December 31, 2014 | -25.45M |
| September 30, 2014 | -35.32M |
| June 30, 2014 | -39.50M |
| March 31, 2014 | -28.26M |
| December 31, 2013 | -17.82M |
| September 30, 2013 | -19.88M |
| June 30, 2013 | -12.00M |
| March 31, 2013 | -14.99M |
| December 31, 2012 | -7.158M |
| September 30, 2012 | -7.805M |
| June 30, 2012 | -5.682M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-242.08M
Minimum
Mar 2024
627.79M
Maximum
Mar 2020
-81.18M
Average
-108.37M
Median
Cash from Operations (Quarterly) Benchmarks
| Eli Lilly and Co | 3.712B |
| Catalyst Pharmaceuticals Inc | 72.87M |
| Regeneron Pharmaceuticals Inc | 1.291B |
| Vertex Pharmaceuticals Inc | 1.370B |
| Viking Therapeutics Inc | -21.96M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -128.82M |
| Cash from Financing (Quarterly) | 13.76M |
| Free Cash Flow | -480.40M |
| Free Cash Flow Per Share (Quarterly) | -1.075 |
| Free Cash Flow to Equity (Quarterly) | -109.21M |
| Free Cash Flow to Firm (Quarterly) | -107.96M |
| Free Cash Flow Yield | -4.18% |